Navigation Links
Innovive Pharmaceuticals Announces Data from Oncology Drug Programs,to be Presented at American Association for Cancer Research Annual,Meeting

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that interim data from a Phase I trial of INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. Additionally, preclinical data on INNO-206, a doxorubicin prodrug for the treatment of various cancers, will be presented. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to these presentations is as follows: -0-

Presentation Title:     "A phase I study of INNO-406, a dual inhibitor

                         of Abl/Lyn kinases, in adult patients with

                         imatinib-resistant or intolerant Philadelphia

                         chromosome positive (Ph+) leukemias"

----------------------- ----------------------------------------------

Abstract Number:        2637

----------------------- ----------------------------------------------

Session:                Poster Section 5, Clinical Research 11, Poster

                         Board #2

----------------------- ----------------------------------------------

Session Date and Time:  Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.

----------------------- ----------------------------------------------

Location:               Exhibit Hall, Los Angeles Convention Center

----------------------- ----------------------------------------------

----------------------- ----------------------------------------------

Presentation Title:     "Reduced chronic cardiotoxicity and

                         mitochondrial damage of the (6-

                         maleimidocaproyl) hydrazone derivative of

                         doxorubicin (DOXO-EMCH) in a rat model

                         compared to doxorubicin"

----------------------- ---------

Abstract Number:        5587

----------------------- ----------------------------------------------

Session:                Poster Section 28, Experimental and Molecular

                         Therapeutics 46, Poster Board #10

----------------------- ----------------------------------------------

Session Date and Time:  Wednesday, April 18, 2007, 8:00 a.m. - 12:00


----------------------- ----------------------------------------------

Location:               Exhibit Hall, Los Angeles Convention Center

----------------------- ----------------------------------------------

About INNO-406

INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.

About INNO-206

INNO-206 (formerly DOXO-EMCH) is a doxorubicin prodrug designed to preferentially reach the tumor and reduce adverse events compared to native doxorubicin. A Phase I study of INNO-206 that demonstrated safety and objective clinical responses in a variety of tumor types was completed in 2005 and presented at the March 2006 Krebskongress meeting in Berlin. In this study, doses were administered at up to six times the standard dosing of doxorubicin without an increase in obser ved side effects over historically seen levels with doxorubicin. Objective clinical responses were seen in patients with sarcoma, breast, and lung cancers.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit


INNOVIVE Pharmaceuticals
Steve Kelly
President and CEO
Porter Novelli Life Sciences
Media & Investor Relations
Rachel Lipsitz


Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
3. Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:12/1/2015)... Texas , Dec. 1, 2015 /PRNewswire/ ...  announced today that top-line data from its ... telotristat etiprate in treating carcinoid syndrome in ... with the clinical benefit observed in its ... designed as a companion to TELESTAR primarily ...
(Date:12/1/2015)... Colo. , Dec. 1, 2015 Ampio ... New York Stock Exchange has established January 5, 2016 as ... its stockholders of the shares of Common Stock of ... (1) share of Aytu common stock for every five ... the record date, December 1, 2015. The distribution date will ...
(Date:12/1/2015)... PUNE, India , December 1, 2015 ... defines and segments the concerned market with analysis and ... orthobiologics report defines and segments the concerned ... According to the Market Research Report "North American ... Bone Growth Factors & Spinal Stimulation, Stem Cell Therapy, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Lutronic, a leading innovator of aesthetic and medical laser ... devices for sale in the United States. Clarity is a Superior Dual Wavelength ... lasers, into a single platform that is easy to own and operate. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , users can ... customization, the possibilities are truly endless, all with a click of a mouse. Each ... flip, horizontal flip, depth of field and more, all within Final Cut Pro X. ...
(Date:11/30/2015)... ... 2015 , ... Third Molar SEO , one of ... launched a sleek, mobile-ready and user-centric redesigned website. , Vivek Srivastava, founder and ... the benefits that its SEO services provide to dentists and why Third Molar ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... The ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized with ... leading networking organization exclusively for professional women, boasting more than 850,000 members and over ...
(Date:11/30/2015)... ... , ... Until now, the St. Louis Fetal Care Institute used ... Study) trial. One of these exclusion criteria was a BMI above 34.9. According to ... is considered normal, 25 - 29.9 is overweight and above 30 is obese. , ...
Breaking Medicine News(10 mins):